De mest almindelige bivirkninger ved brug af degarelix i det bekræftende fase III- forsøg (N=409) skyldtes de forventede fysiologiske virkninger af testosteron suppression, inklusiv hedeture og vægtøgning (rapporteret hos henholdsvis 25% og 7% af de patienter, der modtog behandling i 1 år) eller bivirkninger ved injektionsstedet.
The most commonly observed adverse reactions during degarelix therapy in the confirmatory phase III study (N=409) were due to the expected physiological effects of testosterone suppression, including hot flushes and weight increase (reported in 25% and 7%, respectively, of patients receiving treatment for one year), or injection site adverse events.